PharmaCyte Biotech, Inc., a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of the cancer. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the Cannabis plant. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and is based in Laguna Hills, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone917-595-2850
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees4
Next Earnings Date4/29/2019 (Estimated)
OptionableNot Optionable
Pharmacyte Biotech (OTCMKTS:PMCB) Frequently Asked Questions
What is Pharmacyte Biotech's stock symbol?
Pharmacyte Biotech trades on the OTCMKTS under the ticker symbol "PMCB."
When is Pharmacyte Biotech's next earnings date?
Has Pharmacyte Biotech been receiving favorable news coverage?
Press coverage about PMCB stock has been trending somewhat positive on Friday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Pharmacyte Biotech earned a coverage optimism score of 1.1 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the immediate future.
Who are some of Pharmacyte Biotech's key competitors?
Some companies that are related to Pharmacyte Biotech include Jounce Therapeutics (JNCE), Compugen (CGEN), AVITA MED LTD/S (AVMXY), Neon Therapeutics (NTGN), Erytech Pharma (ERYP), Allena Pharmaceuticals (ALNA), Organovo (ONVO), Brainstorm Cell Therapeutics (BCLI), Oncobiologics (ONS), Surface Oncology (SURF), INmune Bio (INMB), Champions Oncology (CSBR), Fennec Pharmaceuticals (FENC), Nantkwest (NK) and Applied Genetic Technologies (AGTC).
What other stocks do shareholders of Pharmacyte Biotech own?
Who are Pharmacyte Biotech's key executives?
Pharmacyte Biotech's management team includes the folowing people:
- Mr. Kenneth L. Waggoner, Chairman, CEO, Pres, Gen. Counsel & Sec. (Age 71)
- Mr. Carlos A. Trujillo, CFO & Director (Age 61)
- Dr. Gerald W. Crabtree, COO & Director (Age 78)
- Prof. Walter H. Günzburg, Chief Scientific Officer & Consultant (Age 60)
- Dr. Mark L. Rabe, Director of Cannabis Program Devel. and Member of Medical & Scientific Advisory Board
How do I buy shares of Pharmacyte Biotech?
Shares of PMCB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pharmacyte Biotech's stock price today?
One share of PMCB stock can currently be purchased for approximately $0.0417.
How big of a company is Pharmacyte Biotech?
Pharmacyte Biotech has a market capitalization of $46.99 million. Pharmacyte Biotech employs 4 workers across the globe.
What is Pharmacyte Biotech's official website?
How can I contact Pharmacyte Biotech?
Pharmacyte Biotech's mailing address is 23046 AVENIDA DE LA CARLOTA SUITE 600, LAGUNA HILLS CA, 92653. The company can be reached via phone at 917-595-2850 or via email at [email protected]
MarketBeat Community Rating for Pharmacyte Biotech (OTCMKTS PMCB)
MarketBeat's community ratings are surveys of what our community members think about Pharmacyte Biotech and other stocks. Vote "Outperform" if you believe PMCB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PMCB will underperform the S&P 500 over the long term. You may vote once every thirty days.
